ERJ Open Research 2021 March 22 [Link] Lars Hagmeyer, Stephan Schäfer, Marianne Engels, Anja Pietzke-Calcagnile, Marcel Treml, Simon-Dominik Herkenrath, Matthias Heldwein, Khosro Hekmat, Sandhya Matthes, Andreas Scheel, Jürgen Wolf, Reinhard Büttner, Winfried Randerath Abstract Background: Programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) immune checkpoint inhibitors have been approved for monotherapy…

Read More

International Journal of Surgical Pathology 2021 March 17 [Link] Kai-Bo Chen, Ya-Jing Huang, Yi Huang, Zhi-Wei Wu, Xiao-Li Jin, Hang Zhang, Xue-Ping Xiang, Lin Chen, Li Chen Abstract Sarcomatoid malignant mesothelioma (MM) is a rare and aggressive disease, and its diagnosis is challenging. A 60-year-old man presented with a recurrent subcutaneous mass in his right…

Read More

Journal of Thoracic Disease 2021 February [Link] Camila M Baldavira, Juliana Machado-Rugolo, Tabatha G Prieto, Daniel R Bastos, Marcelo Balancin, Alexandre M Ab’Saber, Lygia B Yaegashi, Paola C Souza, Cecilia Farhat, Teresa Y Takagaki, Maria Ap Nagai, Vera L Capelozzi Abstract Background: Pleckstrin homology domain family A (PHLDA) genes play important roles in cancer cellular…

Read More

Human Pathology 2021 March 2 [Link] Hiroe Itami, Tomomi Fujii, Tokiko Nakai, Maiko Takeda, Yohei Kishi, Fumiaki Taniguchi, Chiyoko Terada 2, Fumi Okada, Yuji Nitta, Minami Matsuoka, Shoh Sasaki, Sumire Sugimoto, Tomoko Uchiyama, Kohei Morita, Takahiko Kasai, Ryuji Kawaguchi, Chiho Ohbayashi Abstract Adenomatoid tumors (ATs) are benign mesothelial tumors with good prognosis and usually occur…

Read More

Human Pathology 2021 March 2 [Link] Hiroe Itami, Tomomi Fujii, Tokiko Nakai, Maiko Takeda, Yohei Kishi, Fumiaki Taniguchi, Chiyoko Terada, Fumi Okada, Yuji Nitta, Minami Matsuoka, Shoh Sasaki, Sumire Sugimoto, Tomoko Uchiyama, Kohei Morita, Takahiko Kasai, Ryuji Kawaguchi, Chiho Ohbayashi Abstract Adenomatoid tumors (ATs) are benign mesothelial tumors with good prognosis and usually occur in…

Read More

Thoracic Cancer 2021 March 4 [Link] Jordi Guzmán-Casta, Sonia Carrasco-CaraChards, Jorge Guzmán-Huesca, Carla Paola Sánchez-Ríos, Rodrigo Riera-Sala, José Fabián Martínez-Herrera, Erika Sagrario Peña-Mirabal, Diana Bonilla-Molina, Jorge Arturo Alatorre-Alexander, Luis Manuel Martínez-Barrera, Jerónimo Rafael Rodríguez-Cid Abstract Background: Malignant pleural mesothelioma is an infrequent neoplasia with a poor prognosis and the majority of patients already have advanced…

Read More

Virchows Archiv 2021 February 11 [Link] Zheng Hua Piao, Xin Cheng Zhou, Jia Yi Chen Abstract Sarcomatoid malignant mesothelioma (SMM) tends to occur in the pleura and is morphologically similar to lung sarcomatoid carcinoma (LSC) and organizing pleuritis (OP). Because SMM often does not express mesothelial markers, it is very difficult to distinguish from LSC…

Read More

Thoracic Cancer 2021 February 2 [Link] Takafumi Fukui, Takako Okubo, Naoki Tanimoto, Hiromichi Okuma, Yoshitaka Shiina, Mizuki Kohama, Jun Yamada, Yasuhiro Funada, Yoshihiro Ikura Abstract Here, we report a case of malignant pleural mesothelioma (MPM) that was very difficult to diagnose. A 62-year-old woman with a surgical history of recurrent bilateral pneumothorax was admitted to…

Read More

Acta Oncologica 2021 January 27 [Link] Thomas Ringgaard Petersen, Vasiliki Panou, Christos Meristoudis, Ulla Møller Weinreich, Oluf Dimitri Røe Abstract Background: This study aims to investigate patient- and disease characteristics associated with survival in malignant pleural mesothelioma (MPM) patients with anti-tumor treatment or with best supportive care (BSC). Materials and methods: Consecutive MPM cases diagnosed…

Read More

Cancer Cytopathology 2021 January 25 [Link] Mohammed S I Mansour, Tomas Seidal, Ulrich Mager, Katalin Dobra, Hans Brunnström, Annika Dejmek Abstract Background: Malignant mesothelioma (MM) is a therapy-resistant tumor, often causing an effusion. Drugs targeting the programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway have shown promising results, but assessment of PD-L1…

Read More